| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| desvenlafaxine | Tablet, modified release | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/10/2025 |
| desvenlafaxine | Tablet, modified release | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/10/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 20/10/2025 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 20/10/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 20/10/2025 |
| rifampicin | Capsule, hard | 150 mg | Current | Limited Availability | Manufacturing | 20/10/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| sildenafil citrate | Tablet, uncoated | 35.1 mg | Current | Limited Availability | Manufacturing | 17/10/2025 |
| glipizide | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| mesalazine | Tablet, modified release | 1 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/10/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Limited Availability | Manufacturing | 17/10/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| carbidopa monohydrate~levodopa~entacapone | Tablet, film coated | 54 mg~200 mg~200 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| entacapone~carbidopa monohydrate~levodopa | Tablet, film coated | 200 mg~20.25 mg~75 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| entacapone~levodopa~carbidopa monohydrate | Tablet, film coated | 200 mg~50 mg~13.5 mg | Current | Limited Availability | Manufacturing | 17/10/2025 |
| levodopa~entacapone~carbidopa monohydrate | Tablet, film coated | 100 mg~200 mg~27 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| entacapone~levodopa~carbidopa monohydrate | Tablet, film coated | 200 mg~125 mg~33.75 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| carbidopa monohydrate~levodopa~entacapone | Tablet, film coated | 40.5 mg~150 mg~200 mg | Current | Unavailable | Manufacturing | 17/10/2025 |
| pregabalin | Capsule, hard | 150 mg | Current | Limited Availability | Unexpected increase in consumer demand | 17/10/2025 |
| risperidone | Tablet, film coated | 2 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| gabapentin | Tablet, film coated | 600 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 17/10/2025 |
| amlodipine besilate~olmesartan medoxomil~hydrochlorothiazide | Tablet, film coated | 13.9 mg~40 mg~12.5 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 17/10/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 17/10/2025 |
| prazosin hydrochloride | Tablet, uncoated | 1.095 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| tobramycin | Injection, solution | 80 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| tetracosactide | Injection, modified release | 1 mg/mL | Current | Unavailable | Manufacturing | 16/10/2025 |
| dienogest~ethinylestradiol | Tablet, sugar coated | 2 mg~.03 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| codeine phosphate hemihydrate | Oral Liquid, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 16/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 277.5 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| midazolam | Injection, solution | 5 mg/mL | Anticipated | Available | Manufacturing | 16/10/2025 |
| olsalazine sodium | Capsule | 250 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| finasteride | Tablet, film coated | 1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| lumefantrine~artemether | Tablet, dispersible | 120 mg~20 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 16/10/2025 |
| bisoprolol fumarate | Tablet | 5 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| levetiracetam | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 16/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| sildenafil citrate | Tablet, film coated | 28.1 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Resolved | Available | Manufacturing | 16/10/2025 |
| oxytocin | Injection, solution | 5 IU/mL | Resolved | Available | Unexpected increase in consumer demand | 16/10/2025 |
| oxytocin | Injection, solution | 10 IU/mL | Resolved | Available | Manufacturing | 16/10/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 10.9 mg~10 mg | Resolved | Available | Manufacturing | 16/10/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 16/10/2025 |
| nicorandil | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 16/10/2025 |
| tadalafil | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 16/10/2025 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Anticipated | Available | Manufacturing | 16/10/2025 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Limited Availability | Manufacturing | 16/10/2025 |
| eplerenone | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 16/10/2025 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| ambrisentan | Tablet, film coated | 5 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| olsalazine sodium | Tablet, uncoated | 500 mg | Current | Unavailable | Manufacturing | 16/10/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| hydrochlorothiazide~enalapril maleate | Tablet, uncoated | 6 mg~20 mg | Anticipated | Available | Manufacturing | 16/10/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 1112 mg | Current | Limited Availability | Manufacturing | 16/10/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| galantamine~galantamine hydrobromide | Capsule, modified release | 16 mg~20.51 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2025 |
| diclofenac sodium | Tablet, enteric coated | 50 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 15/10/2025 |
| propranolol hydrochloride | Tablet, film coated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/10/2025 |
| propranolol hydrochloride | Tablet, film coated | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/10/2025 |
| alfentanil hydrochloride | Injection, solution | 1.0876 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 15/10/2025 |
| pregabalin | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 15/10/2025 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 15/10/2025 |
| dabigatran etexilate mesilate | Capsule, hard | 126.83 mg | Resolved | Available | Manufacturing | 15/10/2025 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 15/10/2025 |
| rivaroxaban | Tablet, film coated | 15 mg | Anticipated | Available | Manufacturing | 15/10/2025 |
| levothyroxine sodium | Tablet | 50 microgram | Current | Unavailable | Unexpected increase in consumer demand | 15/10/2025 |
| metronidazole | Tablet, film coated | 400 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 15/10/2025 |
| rifampicin | Capsule, hard | 300 mg | Current | Unavailable | Manufacturing | 15/10/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 15/10/2025 |
| diclofenac sodium | Tablet, enteric coated | 25 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 14/10/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 556.275 mg | Resolved | Available | Manufacturing | 14/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 14/10/2025 |
| ephedrine sulfate | Injection, solution | 30 mg/mL | Anticipated | Available | Manufacturing | 14/10/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Resolved | Available | Manufacturing | 14/10/2025 |
| primaquine phosphate | Tablet, uncoated | 13.2 mg | Anticipated | Available | Manufacturing | 14/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Unavailable | Manufacturing | 14/10/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 20 mg~12.5 mg | Anticipated | Available | Manufacturing | 14/10/2025 |
| atenolol | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 14/10/2025 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 14/10/2025 |
| metoprolol succinate | Tablet, modified release | 23.75 mg | Resolved | Available | Manufacturing | 14/10/2025 |
| levothyroxine sodium | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 14/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 14/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Limited Availability | Manufacturing | 14/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Unavailable | Manufacturing | 14/10/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Anticipated | Available | Manufacturing | 13/10/2025 |
| lidocaine hydrochloride | Injection, solution | 20 mg/mL | Resolved | Available | Manufacturing | 13/10/2025 |
| adrenaline (epinephrine) acid tartrate~lidocaine hydrochloride | Injection, solution | 9.1 microgram/mL~20 mg/mL | Resolved | Available | Manufacturing | 13/10/2025 |
| venlafaxine hydrochloride | Capsule, modified release | 84.86 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 13/10/2025 |
| ethinylestradiol~drospirenone | Tablet | 30 microgram~3 mg | Current | Limited Availability | Manufacturing | 13/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 13/10/2025 |
| milrinone | Injection, concentrated | 10 mg | Current | Limited Availability | Manufacturing | 13/10/2025 |
| irbesartan | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 13/10/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 13/10/2025 |
| potassium chloride | Tablet, modified release | 600 mg | Resolved | Available | Manufacturing | 13/10/2025 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 13/10/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/10/2025 |
| bromazepam | Tablet, uncoated | 6 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 13/10/2025 |
| cisatracurium besilate | Injection, solution | 2.68 mg/mL | Resolved | Available | Manufacturing | 13/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .25 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 13/10/2025 |
| spironolactone | Tablet, film coated | 25 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 13/10/2025 |
2025年10月20日